Jump to content

CJ-1639

From Wikipedia, the free encyclopedia

CJ-1639
Identifiers
  • N-[3-[2-[[(6S)-2-amino-4,5,6,7-tetrahydro-1,3-benzothiazol-6-yl]-propylamino]ethyl]-3-hydroxycyclobutyl]naphthalene-2-carboxamide
CAS Number
PubChem CID
Chemical and physical data
FormulaC27H34N4O2S
Molar mass478.66 g·mol−1
3D model (JSmol)
  • CCCN(CCC1(CC(C1)NC(=O)C2=CC3=CC=CC=C3C=C2)O)[C@H]4CCC5=C(C4)SC(=N5)N
  • InChI=1S/C27H34N4O2S/c1-2-12-31(22-9-10-23-24(15-22)34-26(28)30-23)13-11-27(33)16-21(17-27)29-25(32)20-8-7-18-5-3-4-6-19(18)14-20/h3-8,14,21-22,33H,2,9-13,15-17H2,1H3,(H2,28,30)(H,29,32)/t21?,22-,27?/m0/s1
  • Key:QXYZJXCNTMMWEO-ZVOVCPRUSA-N

CJ-1639 is a drug derived from pramipexole, which acts as a highly potent and selective full agonist for the dopamine D3 receptor. It has a Ki of 3.61 nM and is over 1000x selective for D3 over the D1 and D2 receptors.[1]

References

[edit]
  1. ^ Chen J, Collins GT, Levant B, Woods J, Deschamps JR, Wang S (August 2011). "CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist". ACS Medicinal Chemistry Letters. 2 (8): 620–625. doi:10.1021/ml200100t. PMC 3224040. PMID 22125662.